Starting June 13, 2025, EmblemHealth and ConnectiCare are introducing a new laboratory benefit management reimbursement policy to address therapeutic drug monitoring of 5-Fluorouracil. See:
- EmblemHealth’s Therapeutic Drug Monitoring of 5-Fluorouracil (LBM)
- ConnectiCare’s Therapeutic Drug Monitoring of 5-Fluorouracil (LBM).
The following reimbursement policies have been updated. If the policy does not have a company name shown, the policy applies to both EmblemHealth and ConnectiCare. See their revision histories for effective dates and applicable changes:
- Coronavirus Testing in the Outpatient Setting (LBM)
- Diabetes Mellitus Testing (LBM)
- Diagnosis of Idiopathic Environmental Intolerance (LBM)
- Diagnostic Testing of Iron Homeostasis & Metabolism (LBM)
- EmblemHealth’s Outpatient Diagnostic Imaging Self-Referral Payment Policy
- Immune Cell Function Assay (LBM)
- Immunohistochemistry (LBM)
- Pathogen Panel Testing (LBM)
- Testing of Homocysteine Metabolism-Related Conditions (LBM)
- Testosterone Testing (LBM)
- Vitamin B12 & Methylmalonic Acid Testing (LBM)
- Vitamin D Testing (LBM)
JP 68747 03/2025